Clinics and research in hepatology and gastroenterologyHumansGemcitabineCisplatinDeoxycytidineRetrospective Studies
Clinical and economic outcomes of adding durvalumab to gemcitabine/cisplatin in advanced biliary tract cancers: A multicenter descriptive study.
Lena Luciani, Claire Carlier, Léonie Leuk, Justine Clarenne, Violaine Lepage, Marine Perrier, Olivier Bouché, Elia Gigante, Florian Slimano
Published: 202510.1016/j.clinre.2025.102733
Abstract
BACKGROUND: Durvalumab in combination with gemcitabine/cisplatin (GemCis) has expanded therapeutic options for advanced biliary tract cancers (BTCs), raising both clinical and economic considerations. We aim to describe the efficacy, safety and econo…
Preview only. Read the full abstract at the source